Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine.
Sanchez
M R
MR
New York University School of Medicine, Ronald O. Perelman Department of Dermatology, NY 10016, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002991:Clofazimine / Q000627:therapeutic use*; D003078:Colchicine / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D004363:Drug Utilization; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D010396:Penicillamine / Q000627:therapeutic use*; D011193:Potassium Iodide / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D011193:Potassium Iodide; D007978:Levamisole; D013792:Thalidomide; D002991:Clofazimine; D010396:Penicillamine; D003078:Colchicine